{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"52.9","upperLimit":"82.4","value":"69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site).","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects receive daily dose of 420 mg of Ibrutinib capsules","id":"OG000","title":"Phase1b/Phase 2"}],"paramType":"NUMBER","populationDescription":"Efficacy analyses were performed using the All-treated Population (N = 42)","reportingStatus":"POSTED","timeFrame":"Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.","title":"Phase 2: Overall Response Rate as the Percentage of Participants With Response","type":"PRIMARY","unitOfMeasure":"percentage of participants"}